Coherus BioSciences - Stock Price History | CHRS

Historical daily share price chart and data for Coherus BioSciences since 2021 adjusted for splits. The latest closing stock price for Coherus BioSciences as of October 27, 2021 is 16.07.
  • The all-time high Coherus BioSciences stock closing price was 37.46 on July 22, 2015.
  • The Coherus BioSciences 52-week high stock price is 22.22, which is 38.3% above the current share price.
  • The Coherus BioSciences 52-week low stock price is 12.21, which is 24% below the current share price.
  • The average Coherus BioSciences stock price for the last 52 weeks is 15.83.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Coherus BioSciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 17.9521 18.3200 22.5300 11.6700 17.3800 -3.47%
2019 17.3294 9.1200 23.3700 8.3800 18.0050 98.95%
2018 13.6622 9.5500 20.2500 8.6500 9.0500 2.84%
2017 16.9113 28.0000 29.0500 8.3500 8.8000 -68.74%
2016 22.6571 21.0700 31.5700 12.5400 28.1500 22.60%
2015 26.8400 15.8200 37.4600 15.8200 22.9600 40.69%
2014 14.1076 12.6100 16.3600 12.6100 16.3200 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.254B $0.476B
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86